Key Highlights

  • Amgen (NASDAQ:AMGN) reports third quarter 2026 results after the close on Tuesday, November 3, 2026, against calendar consensus adjusted EPS of USD 5.79. The Market Value is near USD 254.44 billion.
  • Second quarter Revenue reached USD 10.1 billion, a 10 percent gain, and non-GAAP EPS was USD 6.29. For the full year, the company guides to revenue of USD 38.2 billion to USD 39.4 billion and non-GAAP EPS of USD 22.30 to USD 23.50.
  • In the second quarter, Repatha climbed 37 percent to USD 953 million and Evenity gained 38 percent to USD 714 million. Prolia slid 32 percent to USD 759 million as biosimilar competition arrived.
  • Simple arithmetic on the calendar market value: a 5 percent move in either direction would equal about USD 12.7 billion. This is an illustration, not an options-implied estimate.

What the Market Expects

The calendar consensus of USD 5.79 sits below the USD 6.29 non-GAAP EPS reported in the second quarter, so the quarter is either expected to be softer or the figure uses a different basis, and it should be treated as unverified until checked against company guidance. Full-year non-GAAP EPS guidance of USD 22.30 to USD 23.50 leaves room for a wide quarterly range. Amgen (NASDAQ:AMGN) generated USD 3.5 billion of free Cash Flow in the second quarter and made no share repurchases in that period, which makes Capital allocation commentary worth watching. Guidance was unchanged in the second quarter release, so any raise, cut or narrowing on November 3 will be read as a signal on how management sees the back half.

Growth Products Versus Erosion

Volume-driven launches are offsetting erosion in older products. Tezspire rose 42 percent to USD 486 million. Against that, Prolia Volume fell 20 percent and net price fell 12 percent as Biosimilars launched, the net selling price of Enbrel fell 22 percent after Medicare Part D price setting under the Inflation Reduction Act took effect on January 1, 2026, and Otezla sales fell 21 percent. The tension is that loss of exclusivity hits volume and price together, so each quarter tests whether new launches grow fast enough for Amgen (NASDAQ:AMGN) to cover the decline. Operating expenses also included litigation costs, which can move Earnings independent of product sales.

Pipeline, Regulatory Risk and Scenarios

MariTide has multiple Phase 3 studies ongoing, and higher spending on it contributed to R&D growth. The FDA asked Amgen to voluntarily withdraw Tavneos from the U.S. market, and the company requested a hearing and submitted materials on July 23. Two subcutaneous blinatumomab studies paused new enrollment after a partial clinical hold. A bull case combines revenue on track for the guidance range with steady Repatha and Evenity volume. A bear case adds faster Prolia erosion or adverse regulatory news. No peer result was verified for this preview, so there is no read-through to cite, and the move on November 3 will rest on Amgen's own numbers and any guidance change.

Where Things Stand

The company is Amgen (NASDAQ:AMGN), and the answer to the headline question is that it reports a Business in transition rather than in trouble. Repatha, Evenity and Tezspire are growing by more than 35 percent while Prolia, Enbrel and Otezla shrink, so the net result depends on how quickly the two sides balance. Guidance of USD 38.2 billion to USD 39.4 billion in revenue frames the year. Regulatory headlines and MariTide spending are the swing factors to watch on November 3.